Intellia provided a clinical update at ESGCT reporting durable pharmacodynamic activity from its in vivo LNP gene‑editing programs. The company highlighted NTLA‑2002 (lonvo‑z) for hereditary angioedema (HAE), showing sustained reduction of kallikrein levels to below 60% for periods extending beyond two years in treated adults. Chief scientific officer Birgit Schultes emphasized LNP delivery advantages—transient expression, redose capability and liver tropism—and presented safety data showing only transient liver enzyme elevations without serious adverse events. Intellia also noted progress across its pipeline where liver‑directed LNPs enable in‑body gene modification. The results underscore growing momentum for in vivo editing approaches and reinforce Intellia’s strategic shift toward LNP‑based modalities that can be scaled without viral vectors. Data provide a benchmark for regulatory discussions and potential surrogate endpoints in rare disease gene editing trials.